Equillium, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $149.6M
- Price
- $2.36
- % Change (Daily % change from the live per-ticker quote feed.)
- +17.41%
- Volume
- 538.7K
About
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Quick stats
Shares outstanding63.4M
Computed float44.8M
Float / shares70.6%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001746466
Websitehttps://equilliumbio.com
AI Summary
AI-generated1/21
minorbullishearnings
Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Equillium reported Q2 2026 financial results with cash and cash equivalents of $57.2 million, which the company believes will fund operations into 2029. Net loss narrowed to $4.7 million, or $(0.04) per share, compared to a net loss of $5.7 million, or $(0.16) per share, in the prior year period.
Operationally, management expects to initiate a Phase 1 proof-of-mechanism study of EQ504 in Q4 2026, with topline data anticipated roughly six months later. The company also initiated IND-enabling activities for an inhaled formulation of EQ504 and for EQ302 targeting celiac disease.
A Clinical Advisory Board chaired by Professor Bruce Sands, M.D. of Mount Sinai has been established to guide the EQ504 ulcerative colitis program.